Abstract

7.5.3 TRANSLATIONAL METHODOLOGIES DEVELOPMENT PROJECT A large number of molecular abnormalities contribute to the cancer phenotype. Investigators have demonstrated that inhibition of these targets by some compounds affects cancer phenotypes in model systems. What is frequently missing from these efforts is a method to turn an observation, or even a compound, into a drug that can be tested in human clinical trials. This problem is not restricted to cancer therapies, and this has been recognized by the University's AHC. A substantial commitment to the development of new therapies, as outlined above by Dr. Cerra's conceptual framework of """"""""Research Corridors'* has led to the development of two separate new efforts, the Institute of Therapeutic Discovery and Development (ITDD) and the Center for Translational Medicine (CTM). For these developmental funds, we request support for a new technology/methodology resource, termed Translational Methodologies. The purpose is to facilitate translation of basic laboratory studies into the clinic by engaging the ITDD and the CTM in a joint, integrated effort to bring new small molecule inhibitors, drugs, proteins or cells into phase I clinical cancer trials. Funds will be used to provide staff for translational methodologies that will develop specific high priority projects toward phase I trials,

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-14S2
Application #
8533462
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
14
Fiscal Year
2012
Total Cost
$1,776
Indirect Cost
$600

  Institution

Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455

  Publications

Xu, Bin; Magli, Alessandro; Anugrah, Yoska et al. (2018) Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy. Biomaterials 183:54-66
Nikodemova, Maria; Yee, Jeremiah; Carney, Patrick R et al. (2018) Transcriptional differences between smokers and non-smokers and variance by obesity as a risk factor for human sensitivity to environmental exposures. Environ Int 113:249-258
Rashidi, Armin; Shanley, Ryan; Anasetti, Claudio et al. (2018) Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplant :
Lin, Lifeng; Chu, Haitao (2018) Bayesian multivariate meta-analysis of multiple factors. Res Synth Methods 9:261-272
Mondragon-Gonzalez, Ricardo; Perlingeiro, Rita C R (2018) Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery. Dis Model Mech 11:
Kim, J-H; Frantz, A M; Sarver, A L et al. (2018) Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol 16:E176-E184
Jin, Jin; Zhang, Lin; Leng, Ethan et al. (2018) Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. Stat Med 37:3214-3229
Pierpont, Elizabeth I; Hudock, Rebekah L; Foy, Allison M et al. (2018) Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord 10:21
Carlson, Erik S; Upadhyaya, Pramod; Villalta, Peter W et al. (2018) Analysis and Identification of 2'-Deoxyadenosine-Derived Adducts in Lung and Liver DNA of F-344 Rats Treated with the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of its Metabolite 4-(Methylnitrosamino)-1-(3-p Chem Res Toxicol 31:358-370
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267

Showing the most recent 10 out of 1013 publications